Aclaris Therapeutics Stock Price To Earnings To Growth
| ACRS Stock | USD 1.99 0.12 6.42% |
Fundamental analysis of Aclaris Therapeutics allows traders to better anticipate movements in Aclaris Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Aclaris Therapeutics Company Price To Earnings To Growth Analysis
Aclaris Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Aclaris Therapeutics Price To Earnings To Growth | (0.13) X |
Most of Aclaris Therapeutics' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aclaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Aclaris Therapeutics has a Price To Earnings To Growth of -0.13 times. This is 118.31% lower than that of the Pharmaceuticals sector and 94.37% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 102.66% higher than that of the company.
Aclaris Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.Aclaris Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
Aclaris Fundamentals
| Return On Equity | -1.01 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (9.51) % | ||||
| Current Valuation | 83.9 M | ||||
| Shares Outstanding | 108.33 M | ||||
| Shares Owned By Insiders | 2.68 % | ||||
| Shares Owned By Institutions | 86.23 % | ||||
| Number Of Shares Shorted | 5.82 M | ||||
| Price To Earning | (12.14) X | ||||
| Price To Book | 1.54 X | ||||
| Price To Sales | 12.07 X | ||||
| Revenue | 18.72 M | ||||
| Gross Profit | (36.3 M) | ||||
| EBITDA | (51.72 M) | ||||
| Net Income | (132.06 M) | ||||
| Cash And Equivalents | 248.6 M | ||||
| Cash Per Share | 3.73 X | ||||
| Total Debt | 2.6 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.99 X | ||||
| Book Value Per Share | 1.22 X | ||||
| Cash Flow From Operations | (20.07 M) | ||||
| Short Ratio | 4.65 X | ||||
| Earnings Per Share | (1.57) X | ||||
| Price To Earnings To Growth | (0.13) X | ||||
| Target Price | 7.86 | ||||
| Number Of Employees | 61 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 202.58 M | ||||
| Total Asset | 220.33 M | ||||
| Retained Earnings | (902.86 M) | ||||
| Working Capital | 94.36 M | ||||
| Current Asset | 86.52 M | ||||
| Current Liabilities | 1.55 M | ||||
| Net Asset | 220.33 M |
About Aclaris Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.